Primary therapy with single agent bortezomib as induction, maintenance, and re-Induction in patients with high risk myeloma: results of the ECOG E2A02 trial

Single agent bortezomib results in response rates of 51% in patients with newly diagnosed multiple myeloma (MM) and is touted to be especially effective in high-risk disease. We are the first to prospectively explore single agent bortezomib as primary therapy (response rate, maintenance and reinduct...

Descripción completa

Detalles Bibliográficos
Autores principales: Dispenzieri, Angela, Jacobus, Susanna, Vesole, David H., Callandar, Natalie, Fonseca, Rafael, Greipp, Philip R.
Formato: Texto
Lenguaje:English
Publicado: 2010
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2921007/
https://www.ncbi.nlm.nih.gov/pubmed/20535147
http://dx.doi.org/10.1038/leu.2010.129

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2921007/
https://www.ncbi.nlm.nih.gov/pubmed/20535147
http://dx.doi.org/10.1038/leu.2010.129

Ejemplares similares